医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

GenBody America Receives Amendment to FDA Emergency Use Authorization for Updated Point-of-Care Test Kits with Individual Reagents

2022年09月01日 PM10:15
このエントリーをはてなブックマークに追加


 

JURUPA VALLEY, Calif.

GenBody America, LLC, the U.S. affiliate of GenBody, Inc., a South Korean manufacturer of rapid diagnostic tests and reagents for point-of-care applications for COVID-19, today announced that the U.S. Food and Drug Administration (FDA) has made an amendment to the emergency use authorization for the GenBody COVID-19 Ag kit, which has been updated to include prefilled individual reagent tubes for each test device. This significantly streamlines the testing procedure, enhancing the versatility of the test kit in multiple testing environments and offering a new level of accessibility for the GenBody test device.

“We’re very pleased that the FDA has amended our authorizations,” said David Yoo, CEO of Genbody America. “Although the public interest and news cycles may be moving on from COVID-19, this virus is still an ever-present reality for our society and testing is one of our strongest weapons to keep the spread under control. We’re proud to offer a new level of accessibility with our point-of-care kits that equips our customers with individual reagents. This updated kit will make it easier for them to administer within their organizations. With Fall and Winter seasons coming up soon, numbers are bound to rise again and GenBody America plans to do our part to help manage an upcoming surge.”

Recently, GenBody America was granted an extension of shelf-life for their COVID-19 Ag Test by the FDA from 12 months to 21 months after FDA reviewed ongoing studies demonstrating consistent performance of the test device beyond the initial expiration date. GenBody tests have been validated in multiple independently run clinical trials, most recently at Emory University. Ongoing studies are presently underway both to ensure their longer-term integrity as well as their performance against currently circulating variants.

About GenBody America

GenBody America is the U.S. manufacturer for GenBody, Inc., a leading South Korean manufacturer of rapid diagnostic tests and reagents for point-of-care applications for COVID-19 and other diseases. Based in Southern California, GenBody America sells and distributes GenBody’s visually readable, direct nasopharyngeal and anterior nasal swab COVID-19 antigen test kits to point-of-care providers, CLIA-certified labs, and facilities with CLIA waivers across the United States. GenBody’s COVID-19 antigen test is one of a handful of visually readable tests that is EUA authorized by the FDA. GenBody has over 20 years’ experience in the diagnostic industry and vast networks with several key institutes, universities, and hospitals. GenBody’s core strength remains in R&D, while supplying point-of-care providers throughout the world with reliable rapid antigen tests. GenBody America’s U.S. factory is expected to have a production capacity of approximately 300,000 tests per day. The U.S. factory has been funded in part by the NIH Rapid Acceleration of Diagnostics (RADx®) initiative with federal funds from the National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health. The current contract is funded from the Public Health and Social Services Emergency Fund through the Biomedical Advanced Research and Development Authority, HHS Office of the Assistant Secretary for Preparedness and Response, Department of Health and Human Services, under Contract No. 75N92021C00007. For more information on the company, please visit www.genbodyamerica.com. For more information on purchasing tests, please email sales@genbodyamerica.com.

The GenBody COVID-19 Ag Test has been authorized by the FDA under an EUA for use by authorized laboratories, pending full FDA clearance. The product has been authorized only for the detection of proteins from SARS-CoV-2, and not for any other viruses or pathogens. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1).

View source version on businesswire.com: https://www.businesswire.com/news/home/20220901005291/en/

CONTACT

Nicole Rodrigues

NRPR Group – For GenBody

nicole@nrprgroup.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Takeda to Present Data at 64th American Society of Hematology (ASH) Annual Meeting, Demonstrating Commitment to Patients with Hematologic Cancers and Other Blood Diseases
  • 知临集团宣布发行 2023 年到期的 300 万美元可转换票据
  • ZCGの関連会社がユニバーサル・マリン・メディカル・サプライ・インターナショナルを買収
  • BiomeBank Continues Growth Trajectory With Over $10M Capital Raise
  • Medidata推出全新原生应用程序“myMedidata”,加速研究启动并提升患者体验